Avalyn Pharma Inc. (Nasdaq: AVLN) announced it has completed target enrollment of 375 patients in its Phase 2b MIST clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE